Last reviewed · How we verify
TK001
At a glance
| Generic name | TK001 |
|---|---|
| Also known as | anti-VEGF humanized monoclonal antibody injection |
| Sponsor | Jiangsu T-Mab Biopharma Co.,Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration (PHASE1)
- A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TK001 CI brief — competitive landscape report
- TK001 updates RSS · CI watch RSS
- Jiangsu T-Mab Biopharma Co.,Ltd portfolio CI